KA/EN
Register
Medicines reference
Search
Search
Active substance

Clotrimazole

Favourites

Imidazole antifungal. No registration in force in Georgia. Forms: ear drops.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Clotrimazole
Georgian name
კლოტრიმაზოლი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
0 of 3 forms
Products
Aurizon, Marbotis, Otoxolan
Human medicines in Georgia
Cipzol, Clotri-Denk, Diomicete
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Aurizon 3 mg/ml + 10 mg/ml + 0.9 mg/ml, Ear drops

ear drops suspension, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Aurizon

3 mg/ml + 10 mg/ml + 0.9 mg/ml, ear drops suspension, for dogs
Assessed clinical scopeDog · Label-concordant treatment of canine otitis externa caused by marbofloxacin-susceptible bacteria and clotrimazole-susceptible fungi, especially Malassezia pachydermatis, with concurrent control of inflammation · Into the ear
Care settingVeterinary diagnosis and selection after otoscopy and cytology; outpatient administration after cleaning and drying, with day-7 veterinary reassessment and investigation of the underlying cause.
vetman score 7.8/10 Good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A good, evidence-supported once-daily reference option for correctly diagnosed mixed bacterial/fungal canine otitis externa. Its fluoroquinolone component prevents routine first-line use: confirm an intact tympanum, base selection on cytology and susceptibility context, and investigate the underlying disease.

Regulatory and scientific credibility9.0/10

Aurizon is the long-established reference product with current exact EU/EEA and GB veterinary authorisations, a current regulator-hosted SPC, post-authorisation history and direct comparative trials. It is not registered in the checked Georgian or US registers.

Clinical efficacy7.5/10

A 140-dog phase III comparison found the marbofloxacin/clotrimazole/dexamethasone suspension equivalent to an established comparator, with a 58.3% cure rate and advantages in pain, discharge, odour and day-14 assessment. A bilateral Malassezia study also found greater improvement in yeast count, erythema, cerumen and pruritus than antifungal monotherapy. Benefit depends on matching cytology/pathogen susceptibility and addressing the primary cause.

Safety and tolerability7.0/10

Topical exposure is much lower than systemic treatment, but the intact tympanic membrane must be confirmed. Rare mostly transient deafness, local irritation and corticosteroid-related skin thinning, delayed healing, laboratory changes or adrenal suppression are possible; avoid pregnancy/lactation and unnecessary use in growing dogs.

Clinical practicality7.5/10

Ten drops once daily for 7-14 days is simpler than twice-daily alternatives, and the current packs provide one cannula per intended patient. The ear must still be examined, cleaned and dried, the suspension shaken and massaged in, and continuation beyond day 7 requires veterinary reassessment; in-use shelf life is two months.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform otoscopy and verify an intact tympanic membrane before every course. Do not use with a perforated or unvisualised tympanum; stop and reassess urgently for head tilt, nystagmus, ataxia, hearing change or other vestibular signs.
  • Cytology is required in every otitis externa case and should be repeated at recheck. Sample before cleaning; identify and manage allergy, foreign body, parasites, conformation, endocrine disease, otitis media or another primary/perpetuating cause rather than repeatedly suppressing secondary infection.
  • Marbofloxacin is an EMA AMEG Category B fluoroquinolone. Do not use this combination prophylactically or as a routine first choice; use a lower-category topical option when likely effective and document why a fluoroquinolone is required. Culture and susceptibility are especially important with rods, chronic/recurrent disease or poor response.
  • Do not use when resistance to marbofloxacin or clotrimazole is known, or with hypersensitivity to fluoroquinolones, azole antifungals, corticosteroids or excipients. Failure despite correct administration requires diagnosis and susceptibility review, not automatic repetition or prolongation.
  • Avoid use in young growing dogs unless the exceptional need clearly outweighs the risk. Quinolones are associated with weight-bearing cartilage injury and arthropathy in immature animals.
  • Do not use during pregnancy or lactation. Record reproductive status before treatment and choose a suitable alternative for pregnant, breeding or nursing animals.
  • Clean and dry the external canal before dosing, shake the suspension as directed, instil exactly ten drops once daily and massage the ear base gently. Reassess at day 7 before extending to 14 days; use a separate cannula/dropper for each dog and do not continue beyond the labelled course.
  • Rare, usually transient deafness is reported, mainly in older dogs. Establish baseline hearing and neurologic status when relevant; stop and reassess promptly for reduced hearing, pain, marked erythema, vestibular signs or worsening discharge.
  • Prolonged or intensive topical corticosteroid exposure can cause skin thinning, delayed healing, biochemical/haematological changes and adrenal suppression. Avoid duplicate otic/systemic corticosteroids without review and investigate persistent inflammation rather than extending treatment.
  • Avoid skin and eye contact, wash hands after administration and keep the applicator uncontaminated. People hypersensitive to fluoroquinolones, azole antifungals or corticosteroids should avoid handling; seek medical advice after accidental ingestion or persistent exposure symptoms.
Assessment sources
  1. VMD SPC 20252025
  2. Aurizon VMD assessment history2026
  3. Canine otitis phase III comparison2005
  4. Canine Malassezia otitis comparison2006
  5. AIDAP canine otitis guideline2022
  6. AAHA allergic otitis guideline2023
  7. Recurrent canine otitis review2023
  8. EMA AMEG fluoroquinolone category2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin3 mg/ml Clotrimazole10 mg/ml Dexamethasone0.9 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Vetoquinol · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Marbotis 3 mg/ml + 10 mg/ml + 1 mg/ml, Ear drops

ear drops suspension, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.5/10
Good
vetman assessment

Marbotis

3 mg/ml + 10 mg/ml + 1 mg/ml, ear drops suspension, for dogs
Assessed clinical scopeDog · Label-concordant treatment of canine otitis externa caused by marbofloxacin-susceptible bacteria and clotrimazole-susceptible fungi, especially Malassezia pachydermatis, with concurrent control of inflammation · Into the ear
Care settingVeterinary diagnosis and selection after otoscopy and cytology; outpatient administration after cleaning and drying, with day-7 veterinary reassessment and investigation of the underlying cause.
vetman score 7.5/10 Good
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A good authorised generic-hybrid option with regulator-accepted reference equivalence and favourable handling life, but without an independent exact-product outcome trial. Cytology, intact tympanum, antimicrobial stewardship and day-7 reassessment remain essential.

Regulatory and scientific credibility8.5/10

Marbotis has current exact EU/EEA and GB veterinary authorisations, a 2024 regulator-hosted SPC and a public generic-hybrid assessment establishing reference-product equivalence and favourable benefit-risk. It is not registered in the checked Georgian or US registers.

Clinical efficacy7.0/10

The regulator accepted equivalent efficacy claims to Aurizon from matching composition and physicochemical characteristics; the reference combination has comparative canine evidence for bacterial/fungal otitis and Malassezia-associated inflammation. There is no independent exact-product outcome trial, and success still depends on cytology, susceptibility where indicated and control of the underlying cause.

Safety and tolerability7.0/10

Topical exposure is much lower than systemic treatment, but the intact tympanic membrane must be confirmed. Rare mostly transient deafness, local irritation and corticosteroid-related skin thinning, delayed healing, laboratory changes or adrenal suppression are possible; avoid pregnancy/lactation and unnecessary use in growing dogs.

Clinical practicality7.5/10

Ten drops once daily for 7-14 days is manageable and the six-month in-use shelf life limits waste. The ear still requires examination, meticulous cleaning/drying, shaking, dropper filling and massage, and extending beyond day 7 requires veterinary reassessment.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform otoscopy and verify an intact tympanic membrane before every course. Do not use with a perforated or unvisualised tympanum; stop and reassess urgently for head tilt, nystagmus, ataxia, hearing change or other vestibular signs.
  • Cytology is required in every otitis externa case and should be repeated at recheck. Sample before cleaning; identify and manage allergy, foreign body, parasites, conformation, endocrine disease, otitis media or another primary/perpetuating cause rather than repeatedly suppressing secondary infection.
  • Marbofloxacin is an EMA AMEG Category B fluoroquinolone. Do not use this combination prophylactically or as a routine first choice; use a lower-category topical option when likely effective and document why a fluoroquinolone is required. Culture and susceptibility are especially important with rods, chronic/recurrent disease or poor response.
  • Do not use when resistance to marbofloxacin or clotrimazole is known, or with hypersensitivity to fluoroquinolones, azole antifungals, corticosteroids or excipients. Failure despite correct administration requires diagnosis and susceptibility review, not automatic repetition or prolongation.
  • Avoid use in young growing dogs unless the exceptional need clearly outweighs the risk. Quinolones are associated with weight-bearing cartilage injury and arthropathy in immature animals.
  • Do not use during pregnancy or lactation. Record reproductive status before treatment and choose a suitable alternative for pregnant, breeding or nursing animals.
  • Clean and dry the external canal before dosing, shake the suspension as directed, instil exactly ten drops once daily and massage the ear base gently. Reassess at day 7 before extending to 14 days; use a separate cannula/dropper for each dog and do not continue beyond the labelled course.
  • Rare, usually transient deafness is reported, mainly in older dogs. Establish baseline hearing and neurologic status when relevant; stop and reassess promptly for reduced hearing, pain, marked erythema, vestibular signs or worsening discharge.
  • Prolonged or intensive topical corticosteroid exposure can cause skin thinning, delayed healing, biochemical/haematological changes and adrenal suppression. Avoid duplicate otic/systemic corticosteroids without review and investigate persistent inflammation rather than extending treatment.
  • Avoid skin and eye contact, wash hands after administration and keep the applicator uncontaminated. People hypersensitive to fluoroquinolones, azole antifungals or corticosteroids should avoid handling; seek medical advice after accidental ingestion or persistent exposure symptoms.
Assessment sources
  1. VMD SPC 20242024
  2. Marbotis VMD assessment2024
  3. Canine otitis phase III comparison2005
  4. Canine Malassezia otitis comparison2006
  5. AIDAP canine otitis guideline2022
  6. AAHA allergic otitis guideline2023
  7. Recurrent canine otitis review2023
  8. EMA AMEG fluoroquinolone category2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin3 mg/ml Clotrimazole10 mg/ml Dexamethasone0.9 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Vet-Agro · Poland
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Otoxolan 3 mg/ml + 10 mg/ml + 1 mg/ml, Ear drops

ear drops suspension, for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.4/10
Good
vetman assessment

Otoxolan

3 mg/ml + 10 mg/ml + 1 mg/ml, ear drops suspension, for dogs
Assessed clinical scopeDog · Label-concordant treatment of canine otitis externa caused by marbofloxacin-susceptible bacteria and clotrimazole-susceptible fungi, especially Malassezia pachydermatis, with concurrent control of inflammation · Into the ear
Care settingVeterinary diagnosis and selection after otoscopy and cytology; outpatient administration after cleaning and drying, with day-7 veterinary reassessment and investigation of the underlying cause.
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: No · Verified on 15 Oct 2026

A good authorised generic option with regulator-accepted equivalence to Aurizon, but without an independent exact-product outcome trial. Use only after otoscopy and cytology, reserve the fluoroquinolone appropriately and reassess before extending beyond seven days.

Regulatory and scientific credibility8.5/10

Otoxolan has current exact EU/EEA and GB veterinary authorisations, regulator-hosted product information and a public generic dossier accepting qualitative and physicochemical equivalence to Aurizon. It is not registered in the checked Georgian or US registers.

Clinical efficacy7.0/10

The regulator accepted equivalent efficacy claims to Aurizon from matching composition and physicochemical characteristics; the reference combination has comparative canine evidence for bacterial/fungal otitis and Malassezia-associated inflammation. There is no independent exact-product outcome trial, and success still depends on cytology, susceptibility where indicated and control of the underlying cause.

Safety and tolerability7.0/10

Topical exposure is much lower than systemic treatment, but the intact tympanic membrane must be confirmed. Rare mostly transient deafness, local irritation and corticosteroid-related skin thinning, delayed healing, laboratory changes or adrenal suppression are possible; avoid pregnancy/lactation and unnecessary use in growing dogs.

Clinical practicality7.0/10

Ten drops once daily for 7-14 days is manageable, but the viscous suspension requires 30 seconds of shaking, dropper filling, a separate dropper per dog, prior cleaning/drying and veterinary reassessment at day 7. The fixed ten-drop dose and three-month in-use shelf life are practical but not long-acting.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Perform otoscopy and verify an intact tympanic membrane before every course. Do not use with a perforated or unvisualised tympanum; stop and reassess urgently for head tilt, nystagmus, ataxia, hearing change or other vestibular signs.
  • Cytology is required in every otitis externa case and should be repeated at recheck. Sample before cleaning; identify and manage allergy, foreign body, parasites, conformation, endocrine disease, otitis media or another primary/perpetuating cause rather than repeatedly suppressing secondary infection.
  • Marbofloxacin is an EMA AMEG Category B fluoroquinolone. Do not use this combination prophylactically or as a routine first choice; use a lower-category topical option when likely effective and document why a fluoroquinolone is required. Culture and susceptibility are especially important with rods, chronic/recurrent disease or poor response.
  • Do not use when resistance to marbofloxacin or clotrimazole is known, or with hypersensitivity to fluoroquinolones, azole antifungals, corticosteroids or excipients. Failure despite correct administration requires diagnosis and susceptibility review, not automatic repetition or prolongation.
  • Avoid use in young growing dogs unless the exceptional need clearly outweighs the risk. Quinolones are associated with weight-bearing cartilage injury and arthropathy in immature animals.
  • Do not use during pregnancy or lactation. Record reproductive status before treatment and choose a suitable alternative for pregnant, breeding or nursing animals.
  • Clean and dry the external canal before dosing, shake the suspension as directed, instil exactly ten drops once daily and massage the ear base gently. Reassess at day 7 before extending to 14 days; use a separate cannula/dropper for each dog and do not continue beyond the labelled course.
  • Rare, usually transient deafness is reported, mainly in older dogs. Establish baseline hearing and neurologic status when relevant; stop and reassess promptly for reduced hearing, pain, marked erythema, vestibular signs or worsening discharge.
  • Prolonged or intensive topical corticosteroid exposure can cause skin thinning, delayed healing, biochemical/haematological changes and adrenal suppression. Avoid duplicate otic/systemic corticosteroids without review and investigate persistent inflammation rather than extending treatment.
  • Avoid skin and eye contact, wash hands after administration and keep the applicator uncontaminated. People hypersensitive to fluoroquinolones, azole antifungals or corticosteroids should avoid handling; seek medical advice after accidental ingestion or persistent exposure symptoms.
Assessment sources
  1. VMD SPC 20242024
  2. Otoxolan VMD assessment2016
  3. Canine otitis phase III comparison2005
  4. Canine Malassezia otitis comparison2006
  5. AIDAP canine otitis guideline2022
  6. AAHA allergic otitis guideline2023
  7. Recurrent canine otitis review2023
  8. EMA AMEG fluoroquinolone category2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Marbofloxacin3 mg/ml Clotrimazole10 mg/ml Dexamethasone0.9 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Krka · Slovenia
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗